16 results about "Hypoplasia" patented technology

The utility model provides a bone anchorage type maxillary distraction osteogenesis device which comprises a spiral expansion device, and a rear base plate of the spiral expansion device is fixed to the rear half section of the maxillary bone through a left anchorage nail and a right anchorage nail. The front base plate and the rear base plate are respectively connected with at least two belt rings through belt ring connecting rods, the left front belt ring and the right front belt ring connected with the front base plate are at least sleeved on the first front molars on the corresponding sides, and the left rear belt ring and the right rear belt ring connected with the rear base plate are sleeved on the first molars and / or the second molars on the corresponding sides; the two front band rings are connected through a labial arch, and a lip baffle is fixed in the middle of the labial arch; a traction hook matched with a front tractor is fixedly connected to the outer ring face of the rear belt ring. According to the utility model, the osteotomy gap between the first premolar and the second premolar can be stably and effectively stretched, so that the aim of correcting skeletal hypoplasia or repairing bone defects is fulfilled.

The present invention relates to methods for the treatment of a spinal deformity, such as thoracolumbar deformity in a subject in need of said treatment, said method comprising the step of administering a therapeutically effective amount of an inhibitor of FGFR3 signaling, or an NPR-B agonist and / or an NPR-C agonist to said subject.

The present invention relates to a method of treating spinal malformation, such as thoracolumbar malformation, in a subject in need of such treatment, comprising the step of administering to the subject a therapeutically effective amount of an FGFR3 signaling inhibitor or an NPR-B agonist and / or an NPR-C agonist.

This invention provides compounds of the following formula for treating systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:

The present invention relates to FGFR3 inhibitor compounds, and specifically provides compounds of the following formula: for use in the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), cartilage insufficiency, lethal insufficiency (e.g., Type I), severe cartilage insufficiency (SADDAN) accompanied by developmental retardation and rosmarthosis, muenke syndrome, or cancer.

The present invention relates to an FGFR3 selective inhibitor compound or a pharmaceutically acceptable salt thereof. The compound can be used for treating cancer such as urothelial cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans, or Muenke syndrome.

The present invention relates to structurally novel FGFR3 inhibitor compounds or pharmaceutically acceptable salts, isotopologues, tautomers, stereoisomers or prodrugs thereof, and their use as medicaments. The compounds can be used for the treatment of cancer such as urothelial cancer, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, severe achondroplasia with developmental delays and acanthocytosis or Muenke syndrome.

Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.

The present disclosure provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

This invention relates to novel FGFR3 inhibitor compounds or their pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, or prodrugs, and their use as medicine. These compounds can be used to treat cancers such as urothelial carcinoma, systemic sclerosis, fibrosis, pulmonary fibrosis, achondroplasia, lethal dysplasia, severe achondroplasia with developmental delay and acanthosis nigricans, or Muenke syndrome.

This invention relates to FGFR3 inhibitor compounds, and specifically, provides compounds of the following formula for the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:

This invention relates to the field of therapeutic drugs and systems for nervous system diseases, specifically to the application of Nrf2 in the preparation of therapeutic systems for treating nervous system diseases caused by tRNA synthetase deficiency. Through research on tRNA synthetase-deficient mutants, we discovered that tRNA synthetase deficiency causes a reduction in the size of the mesencephalon in zebrafish, resulting in symptoms of cerebellar hypoplasia and cerebral atrophy. In-depth research on the Perk signaling pathway involved in the above process revealed that the nfe2l2b gene and the Nrf2 protein are key factors regulating neural development, and their downstream target gene is p53. The inventors further applied the nfe2l2 gene to the preparation of therapeutic systems for treating nervous system diseases and to related drug screening, solving the technical problem of the lack of effective treatments for nervous system diseases caused by tRNA synthetase deficiency in the prior art, and possessing ideal value for widespread application.

Compositions and methods are disclosed herein for the treatment of neurocognitive disorders or central nervous system (CNS) disorders such as Alzheimer's disease (AD) and congenital heart diseases such as hypoplastic left heart syndrome (HLHS) with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers.

1. Name of this design product: Infraorbital nasal base integrated prosthesis. 2. Purpose of this design: To fill in the skeletal hypoplasia of the maxilla. 3. The key point of the design of this product lies in its shape. 4. The image or photograph that best illustrates the design's key points: 3D model 4.

This invention relates to FGFR3 inhibitor compounds, and specifically, provides compounds of the following formula for the treatment of systemic sclerosis, fibrosis (e.g., pulmonary fibrosis), achondroplasia, lethal dysplasia (e.g., type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), Muenke syndrome, or cancer:

The invention discloses a CNP analogue and application thereof. According to the CNP analogue, a fatty acid side chain is coupled to a modified CNP peptide main chain, NPR-B agonist activity is reserved, the CNP analogue has a long half-life period, administration is more convenient, immunogenicity is smaller, irritation to an injection site is smaller, 50 nmol / kg of the CNP analogue is injected subcutaneously to a mouse, the effect of improving growth retardation caused by cartilage hypoplasia is better than that of drugs on the market, and the CNP analogue has a good application prospect. Moreover, the CNP analogue can also be used for treating various diseases which can be treated by CNP.